

MYELOID NEOPLASIA

A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia

Laurène Fenwarth,¹ Xavier Thomas,² Stéphane de Botton,³ Nicolas Duployez,¹ Jean-Henri Bourhis,³ Auriane Lesieur,¹ Gael Fortin,⁴ Paul-Arthur Meslin,⁴ Ibrahim Yakoub-Agha,⁵ Pierre Sujobert,⁶ Pierre-Yves Dumas,⁷ Christian Récher,⁸ Delphine Lebon,⁹ Céline Berthon,^{1,10} Mauricette Michallet,² Arnaud Pigneux,⁷ Stéphanie Nguyen,¹¹ Sylvain Chantepie,¹² Norbert Vey,¹³ Emmanuel Raffoux,¹⁴ Karine Celli-Lebras,¹⁵ Claude Gardin,¹⁶ Juliette Lambert,¹⁷ Jean-Valère Malfuson,¹⁸ Denis Caillot,¹⁹ Sébastien Maury,²⁰ Benoît Ducourneau,^{1,21} Pascal Turlure,²² Emilie Lemasle,²³ Cécile Pautas,²⁰ Sylvie Chevret,²⁴ Christine Terré,²⁵ Nicolas Boissel,²⁶ Gérard Socié,²⁷ Hervé Dombret,¹⁴ Claude Preudhomme,^{1,*} and Raphael Itzykson^{4,14,*}

¹Unité Mixte de Recherche (UMR) 9020–UMR1277, Canther–Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, Centre National de la Recherche Scientifique (CNRS), INSERM, Centre Hospitalo-Universitaire (CHU) Lille, Institut de Recherche sur le Cancer de Lille (IRCL), Lille, France; ²Service d'Hématologie Clinique, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France; ³Département d'Hématologie, Institut Gustave Roussy, Villejuif, France; ⁴Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France; ⁵CHU de Lille, University of Lille, INSERM U1286, Infnite, Lille, France; ⁶Service d'Hématologie Biologique, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France; ⁷Service d'Hématologie et Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France; ⁸Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer Toulouse–Oncopole, Toulouse, France; ⁹Service d'Hématologie Clinique, CHU Amiens, Amiens, France; ¹⁰Service d'Hématologie, CHU Lille, Lille, France; ¹¹Service d'Hématologie Clinique, Hôpital Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris, France; ¹²Service d'Hématologie Clinique, CHU Caen, Caen, France; ¹³Service d'Hématologie, Institut Paoli-Calmettes, Marseille, France; ¹⁴Service Hématologie Adultes, Hôpital Saint-Louis, AP-HP, Paris, France; ¹⁵Acute Leukemia French Association Coordination Office, Institut de Recherche Saint-Louis (IRSL), Hôpital Saint-Louis, Paris, France; ¹⁶Service d'Hématologie Clinique, Hôpital Avicenne, AP-HP, Bobigny, France; ¹⁷Département d'Hématologie Clinique, Hôpital André Mignot, Centre Hospitalier de Versailles, Le Chesnay, France; ¹⁸Service d'Hématologie Clinique, Hôpital d'Instruction des Armées Percy, Clamart, France; ¹⁹Service d'Hématologie Clinique, CHU Dijon, Dijon, France; ²⁰Service d'Hématologie Clinique, Hôpital Henri Mondor, AP-HP, Créteil, France; ²¹Laboratoire d'Hématologie, CH Valenciennes, Valenciennes, France; ²²Service d'Hématologie Clinique, CHU Limoges, Limoges, France; ²³Service d'Hématologie, Centre Henri Becquerel, Rouen, France; ²⁴Service de Biostatistiques et Informatique Médicale, Hôpital Saint-Louis, AP-HP, Paris, France; ²⁵Laboratoire d'Hématologie, CH Versailles, Le Chesnay, France; and ²⁶Service Hématologie Adolescents Jeunes Adultes and ²⁷Service Hématologie Greffe, Hôpital Saint-Louis, AP-HP, Paris, France

KEY POINTS

- A KB algorithm provides more accurate outcome prediction than the current ELN risk stratification.
- The decision to perform HSCT in first CR in AML can be personalized by integrating ELN 2017 risk, *NPM1* MRD, and KB simulation.

A multistage model instructed by a large dataset (knowledge bank [KB] algorithm) has recently been developed to improve outcome predictions and tailor therapeutic decisions, including hematopoietic stem cell transplantation (HSCT) in acute myeloid leukemia (AML). We assessed the performance of the KB in guiding HSCT decisions in first complete remission (CR1) in 656 AML patients younger than 60 years from the ALFA-0702 trial (NCT00932412). KB predictions of overall survival (OS) were superior to those of European LeukemiaNet (ELN) 2017 risk stratification (C-index, 68.9 vs 63.0). Among patients reaching CR1, HSCT in CR1, as a time-dependent covariate, was detrimental in those with favorable ELN 2017 risk and those with negative *NPM1* minimal residual disease (MRD; interaction tests, $P = .01$ and $P = .02$, respectively). Using KB simulations of survival at 5 years in a scenario without HSCT in CR1 (KB score), we identified, in a similar time-dependent analysis, a significant interaction between KB score and HSCT, with HSCT in CR1 being detrimental only in patients with a good prognosis based on KB simulations (KB score ≥ 40 ; interaction test, $P = .01$). We could finally integrate ELN 2017, *NPM1* MRD, and KB scores to sort 545 CR1 patients into 278 (51.0%) HSCT candidates and 267 (49.0%) chemotherapy-only candidates. In both time-dependent and 6-month landmark analyses, HSCT significantly improved OS in HSCT candidates, whereas it significantly shortened OS in chemotherapy-only candidates. Integrating KB predictions with ELN 2017 and MRD may thus represent a promising approach to optimize HSCT timing in younger AML patients. (*Blood*. 2021;137(4):524-532)

Introduction

The decision to proceed to allogeneic stem cell transplantation (HSCT) is the mainstay of precision medicine in acute myeloid leukemia (AML) patients younger than 60 years

achieving a first complete remission (CR1) with intensive chemotherapy.^{1,2}

Risk stratification was initially based on a limited set of cytogenetic and genetic lesions.³⁻⁵ The recent European LeukemiaNet (ELN)

2017 stratification also accounts for the allelic ratio of *FLT3* internal tandem duplications (*FLT3*-ITDs)⁶⁻⁹ and mutations in *TP53*, *RUNX1*, or *ASXL1*.¹⁰

Current guidelines on the timing of HSCT in AML have been informed by pivotal donor vs no donor studies, demonstrating that, in patients with favorable risk, HSCT led to similar long-term outcome compared with other postremission therapies.¹⁰⁻¹³ These genetic randomization studies became less relevant with the expanding use of donors others than HLA-identical siblings.^{14,15} Authors have also considered HSCT as a time-dependent covariate to control for the immortal time bias.¹⁶⁻¹⁹

Collectively, these studies confirmed the benefit of HSCT in adverse-risk patients, with conflicting data for intermediate-risk patients. None of them identified a subset of patients with a significant benefit of chemotherapy-based consolidation compared with HSCT.^{11-13,16-18}

Minimal residual disease (MRD) is also increasingly used to predict the benefit of HSCT in AML. Transcript-based MRD can identify the subset of *NPM1*-mutated patients who benefit from HSCT.²⁰

Papaemmanuil et al²¹ previously described the mutational landscape of 111 genes in 1540 AML patients accrued between 1993 and 2004 in German-Austrian AML Study Group (AMLSG) trials. Gerstung et al²² applied a multistage model with random effects in this cohort to generate a knowledge bank (KB) that integrates clinical, cytogenetic, genetic, and treatment (HSCT) variables. The resulting KB algorithm generates personalized survival simulations.²² Because of improvements in AML management since accrual of this training cohort,²³ KB simulations may not necessarily match the outcome of patients treated in more recent years. However, KB predictions, used as continuous prognostic scores, have been shown to predict prognosis more accurately than ELN risk stratifications.^{22,24}

The KB algorithm can also simulate the survival of a given patient in different treatment scenarios, including HSCT in CR1 or HSCT deferred beyond relapse. Gerstung et al²² proposed to use the differences between these simulations to estimate the benefit of HSCT in CR1. Whether the KB algorithm can indeed identify HSCT candidates has yet to be validated. Here we integrate KB predictions with ELN 2017 and *NPM1* MRD to identify patients benefiting from HSCT in CR1 in a cohort of 656 patients prospectively enrolled in the ALFA-0702 trial.

Methods

Patients and treatment

The ALFA-0702 trial (clinicaltrials.gov, #NCT00932412) was a phase 2 multicenter randomized study including 18- to 59-year-old patients with newly diagnosed de novo AML, excluding acute promyelocytic and core binding factor leukemias. Patients achieving CR defined per international criteria²⁵ or CR with incomplete platelet recovery (platelet count $<100 \times 10^9/L$, CRp)²⁶ after a daunorubicin and cytarabine timed sequential induction chemotherapy (with or without a high-dose cytarabine-based salvage course) and with protocol-defined nonfavorable risk (supplemental Table 1 available on the *Blood* Web site), were

eligible for HSCT in first CR/CRp (henceforth, CR1). In the absence of HLA-matched donor (sibling or 10/10 matched unrelated donor) or if otherwise ineligible for HSCT, they were randomly assigned to receive either 3 cycles of high-dose cytarabine (HDAC) or 3 cycles of clofarabine associated with intermediate-dose cytarabine (CLARA) as consolidation regimen. Patients with protocol-defined favorable risk were not randomized and received 3 HDAC cycles. Results of the CLARA randomization have previously been published.²⁷ Of 713 patients included in the trial, 656 (92.0%) had DNA available at inclusion for centralized genomic analyses (supplemental Figure 1).

Targeted sequencing

Bone marrow samples from AML patients at diagnosis were studied by targeted sequencing of 41 recurrently mutated genes (supplemental Table 2). All diagnosis samples were screened for the presence of *FLT3*-ITDs by fragment analysis as previously described.²⁰ High and low *FLT3*-ITDs were defined per ELN 2017 guidelines.¹⁰ More than 50 recurrent gene rearrangements and *KMT2A* partial tandem duplications (*KMT2A*-PTD) were sought using ligation-dependent reverse transcriptase-polymerase chain reaction amplification.²⁸ Further details are provided in the supplemental Appendix.

NPM1 MRD

Methods are detailed in the supplemental Appendix. A >4 log reduction in peripheral blood MRD after the first induction course was used to define MRD negativity, a threshold previously shown to indicate HSCT benefit in patients with both typical (A/B/D) and nontypical *NPM1* mutations.²⁰

Definitions

ELN 2017 classification was applied retrospectively after central review of cytogenetics and gene mutations, accounting for reverse transcriptase-polymerase chain reaction results when available.¹⁰ Conditioning regimens were classified as myeloablative or reduced intensity according to recommendations.²⁹

KB algorithm

Variables were recoded according to Gerstung et al.²² Missing data were imputed as previously reported,^{22,24} using the original AMLSG dataset that served to derive the KB algorithm.²¹ We then ran the KB algorithm as published,²² to simulate the survival of each patient in the absence of HSCT in CR1. We further refer to the 5-year overall survival (OS) from diagnosis estimated by these simulations as the KB score, a continuous variable ranging from 0 to 100, with lower KB score indicating worse prognosis. Further KB simulations are indicated in the supplemental Methods and supplemental Table 3.

Statistical analysis

Data are summarized as numbers and percentages or medians and ranges or interquartile ranges (IQR). Group comparisons were carried with Fisher tests for categorical variables and Mann-Whitney or Kruskal-Wallis tests for continuous variables with 2 or >2 groups, respectively. OS was defined as the time interval between inclusion in the ALFA-0702 trial and death or loss of follow-up. Disease-free survival (DFS) was computed from the date of CR1 until relapse, death, or loss to follow-up, whichever came first. Survival distributions were done with the Kaplan-Meier estimator. Follow-up was computed with the inverse

method.³⁰ Univariate and multivariate analyses were carried with log-rank tests and Cox models, respectively. The proportional hazard assumption was validated by visual inspection and testing of Schönfeld residuals.³¹ Multicollinearity was inspected by studying the variance inflation factor, considering variance inflation factor >4 as unacceptable.³² To measure the goodness-of-fit of prognostic models, Harrell's concordance indexes (C-indexes)³³ were obtained after bootstrap cross-validation trained from 100 samples, with R package "pec." The impact of HSCT on OS was studied in patients reaching CR1, with a landmark at 45 days from inclusion considering HSCT in CR1 as a time-dependent covariate, using the method of Simon-Makuch for survival curves³⁴ and the Mantel-Byar method for group comparisons.³⁵ Multivariate analyses were carried with Andersen-Gill models.³⁶ Interaction analyses between HSCT and covariates were tested by introducing interaction terms in multivariable models and forest plots displayed with the R package "anoint." Analyses were performed with R 3.5.3 (cran.r-project.org).

Results

Patient characteristics

Median age of the 656 genotyped patients was 46 years (range, 18-60 years; Table 1), comparable to the 57 patients without centralized genomics (supplemental Table 4). Of 147 (22.4%) *FLT3*-ITD patients, 87 (13.3%) and 60 (9.1%) had low (<0.5) and high (≥ 0.5) allelic ratios, respectively (supplemental Figure 2). ELN 2017 risk was favorable, intermediate, and adverse in 231 (35.2%), 194 (29.6%), and 222 (33.8%) patients, respectively. Nine (1.4%) patients were not classified by ELN 2017 because of missing cytogenetics and lack of stratifying mutation (supplemental Table 5). With a median follow-up of 4.2 years (95% confidence interval [CI], 4.0-4.4), 5-year OS was 58.2% (95% CI, 54.3% to 62.4%). CR1 was achieved in 563 (85.8%) patients after 1 (N = 525) or 2 (N = 38) courses. Median interval between inclusion and CR1 was 45 days (range, 23-124 days). A population of 545 CR1 patients could be analyzed for HSCT benefit after exclusion of the 9 patients with unknown ELN 2017 risk and of 9 patients relapsing before the day 45 landmark chosen for those analyses (HSCT-eligible population; Table 1; supplemental Figure 1). Their 5-year DFS and OS from CR1 were 56.1% (95% CI, 51.7% to 60.8%) and 64.9% (95% CI, 60.5% to 69.6%), respectively. Ninety-one (16.7%) received CLARA instead of HDAC courses.

Prognostic role of ELN 2017 classification

Five-year OS was 77.0% (95% CI, 71.7% to 82.7%), 57.0% (95% CI, 50.0% to 64.9%), and 40.0% (95% CI, 33.4% to 47.8%) in patients with favorable, intermediate, and adverse risk, respectively (log-rank test $P < 10^{-5}$; supplemental Figure 3A). CR1 was achieved in 219 (94.8%) favorable, 166 (85.6%) intermediate, and 160 (72.1%) adverse ELN 2017 risk patients ($P < 10^{-5}$). DFS also varied significantly according to ELN 2017 risk with 5-year estimates of 72.1% (95% CI, 66.4% to 78.4%), 53.7% (95% CI, 46.3% to 62.3%), and 36.3% (95% CI, 28.1% to 46.8%) in patients with favorable, intermediate, and adverse risk, respectively (overall log-rank test $P < 10^{-5}$; supplemental Figure 3B). Differences in CR rates, OS, and DFS according to *FLT3*-ITD allelic ratio did not reach statistical significance (supplemental Figure 4).

Prognostic value of the KB algorithm

Of the 100 variables (16 clinical, 26 cytogenetic, and 58 molecular) that can instruct KB predictions, 3 clinical (lactate dehydrogenase, hemoglobin, splenomegaly) and 24 genetic variables were unavailable. The mutation frequency of these 24 genes was at most 5.4% in the AMLSG cohort that served to develop the KB.²² Data in the remaining 73 variables were missing in less than 5% of patients. After imputation of missing data as recommended by Gerstung et al,²² we derived for each patient a KB score ranging from 0 to 100, with lower values potentially indicating worse prognosis (supplemental Figure 5). As a continuous variable, a higher KB score was associated with a lower risk of death (OS: hazard ratio [HR] = 0.65; 95% CI, 0.60-0.71 for a 10% increase in KB score; $P < 10^{-5}$) or failure beyond CR (DFS: HR = 0.74; 95% CI, 0.68-0.80; $P < 10^{-5}$). For graphical purposes, we binned KB scores in 3 arbitrary groups. Patients with a KB score <20 (N = 180), 20 to 39 (N = 268), or ≥ 40 (N = 208) had 5-year OS of 31.9% (95% CI, 25.4% to 40.2%), 57.5% (95% CI, 51.4% to 64.4%), and 81.6% (95% CI, 76.2% to 87.4%); log-rank test $P < 10^{-5}$; Figure 1A), and 5-year DFS of 37.0% (95% CI, 29.4% to 46.5%), 51.1% (95% CI, 43.3% to 60.3%), and 73.1% (95% CI, 67.0% to 79.8%); log-rank test $P = .004$; Figure 1B). ELN 2017 risk stratification and KB score (as a continuous variable) were correlated with median KB scores of 45.2 (IQR, 35.1-57.8), 29.3 (IQR, 21.1-37.0), and 18.3 (IQR, 7.0-28.8) in patients with favorable, intermediate, and adverse ELN 2017, respectively ($P < 10^{-5}$; supplemental Figure 6). As a continuous variable, the KB score had increased predictive value compared with ELN 2017 stratification, with bootstrapped C-indexes of 68.9 vs 63.0, respectively, for OS and 65.4 vs 60.4, respectively, for DFS. Even after arbitrary discretization as in Figure 1, the bootstrapped C-indexes of KB score categories were 67.0 and 62.5 for OS and DFS, respectively, and thus still superior to ELN 2017 (63.0 and 60.4, respectively).

Prediction of HSCT benefit with MRD-adjusted ELN 2017 risk

Of the 545 patients eligible for HSCT in CR1, 276 (50.6%) were transplanted in CR1, including 53, 106, and 117 patients with favorable, intermediate, and adverse ELN 2017 risk, corresponding to 24.2%, 63.9%, and 73.1% of each risk group, respectively. HSCT was done after myeloablative (N = 178) or reduced intensity (N = 94) conditioning (conditioning not available in N = 4) from a matched related donor (N = 120), a matched unrelated donor (N = 137), or an alternative donor (N = 19).

Considering HSCT as a time-dependent covariate in a bivariate analysis adjusted on ELN 2017 risk, the impact of HSCT was detrimental on OS from the day 45 landmark in patients with favorable risk AML (HR = 2.78; 95% CI, 1.50-5.12; $P = .001$) and overall neutral in those with intermediate (HR = 0.68; 95% CI, 0.40-1.13; $P = .14$) or adverse risk (HR = 0.87; 95% CI, 0.53-1.45; $P = .59$), with a significant interaction between ELN 2017 risk categories and HSCT ($P = .01$; Figure 2).

MRD was available in 143 (65.0%) of the 220 *NPM1*-mutated patients eligible for HSCT in CR1. Of those, 106 (74.1%) had a negative MRD after the first induction course. As previously published,²⁰ there was a significant interaction between MRD and HSCT benefit (interaction test, $P = .02$), with MRD negativity being associated with a significant detriment of HSCT

Table 1. Study population

Characteristic	Total genotyped (N = 656)		HSCT eligible (N = 545)	
	N or median	Percentage or range	N or median	Percentage or range
Age, y	46	18-60	46	18-60
Sex				
Male	351	53.5	285	52.3
Female	305	46.5	260	47.7
ECOG PS				
0	284	43.3	233	42.8
1	298	45.5	250	45.9
2-3	66	10	56	10.2
NA	8	1.2	6	1.1
WBC, 10 ⁹ /L	8.4	0.3-377.4	8.7	0.3-377.4
ELN 2017 risk				
Favorable	231	35.2	219	40.2
Intermediate	194	29.6	166	30.4
Adverse	222	33.8	160	29.4
Missing	9	1.4	0	0

ECOG, Eastern Cooperative Oncology Group; NA, not available; PS, performance status.

(HR = 4.37; 95% CI, 1.71-11.17; $P = .002$; Figure 2). We next considered an MRD-adjusted ELN 2017 risk stratification to identify a potential benefit of HSCT in CR1. Fourteen patients with intermediate ELN 2017 risk but negative MRD were reassigned to the favorable risk group and 27 patients with favorable ELN 2017 risk but a positive MRD to the intermediate risk group, resulting in a total of 206 favorable-risk chemotherapy-only candidates, and 339 HSCT candidates (step 2, Figure 3). Of those, 215 (63.4%) HSCT candidates and 61 (29.6%) chemotherapy-only candidates were transplanted in CR1 based on ALFA-0702 recommendations and investigator's choice (supplemental Figure 7A). In a time-dependent analysis, the impact of HSCT on OS from the day 45 landmark was not significantly beneficial in the 339 HSCT candidates (HR = 0.80; 95% CI, 0.57-1.12; $P = .19$) and was significantly detrimental in the 206 chemotherapy-only candidates (HR = 4.21; 95% CI, 2.16-8.20; $P < 10^{-5}$), again with a significant interaction between the postremission stratification and HSCT ($P = 3 \times 10^{-5}$; supplemental Figure 7B). Therefore, an *NPM1* MRD-adjusted ELN 2017 risk classification can identify patients for whom HSCT in CR1 is detrimental but is not sufficient to robustly identify patients benefiting from HSCT in CR1.

Prediction of HSCT benefit with the KB algorithm

We next investigated whether the KB algorithm could identify patients benefiting from HSCT in CR1. We first attempted to validate the approach published by Gerstung et al, where the KB algorithm is used to simulate the survival of each patient with vs without HSCT in CR1 (see "Methods"), and differences in simulated survival are used to guide HSCT decision. This first approach was not validated in our dataset (details in supplemental Methods, supplemental Results, and supplemental Figure 8). Because the benefit of HSCT is often confined to patients with poorer prognosis and because of the strong prognostic value of the KB score, we alternatively inspected whether a lower KB score could predict HSCT benefit. A systematic inspection of various cutoffs for the KB score identified a threshold value

of 40 as optimal for the discrimination of HSCT benefit (supplemental Methods; supplemental Figure 9). Of the 545 patients eligible for HSCT in CR1, 355 (65.1%) had a KB score <40, of whom 218 (61.4%) were actually transplanted in CR1. In those 355 patients, there was no significant benefit of HSCT in CR1 (HR = 0.93; 95% CI, 0.67-1.29; $P = .68$), whereas HSCT was detrimental in the 190 patients with a KB score of 40 or higher (HR = 3.00; 95% CI, 1.38-6.50; $P = .005$), with a significant interaction between HSCT and this KB score threshold ($P = .01$; Figure 2).

HSCT decision integrating ELN 2017, MRD, and the KB score

We finally sought to combine the MRD-adjusted ELN stratification with this KB score threshold to optimally identify patients in whom HSCT in CR1 induces a survival benefit. For that purpose, we further refined the definition of HSCT candidates as those with nonfavorable MRD-adjusted ELN risk and a KB score less than 40. Although there was still a significant association between a KB score <40 and higher MRD-adjusted risk (Fisher test, $P < 10^{-5}$; supplemental Figure 10), 47 (26.3%) of the 179 patients with intermediate MRD-adjusted risk and 14 (8.8%) of the 160 adverse risk patients had a KB score ≥ 40 and were reclassified as chemotherapy-only candidates, leaving 278 (51.0%) of the 545 patients as HSCT candidates and the remaining 267 (49.0%) patients as chemotherapy-only candidates (step 3, Figure 3). Among intermediate-risk patients, HSCT candidates were significantly older ($P < 10^{-5}$), had higher bone marrow blast percentages ($P = .0009$), more frequent spliceosome gene mutations (14.4% vs 0%, $P = .004$), and less frequent *NPM1* mutations (21.2% vs 42.6%, $P = .007$) than chemotherapy-only candidates. Among adverse-risk patients, the 14 patients that were predicted not to benefit from transplant in CR1 were younger ($P < 10^{-5}$) and more frequently harbored *KMT2A-PTD* (21.4% vs 4.1%, $P = .03$) but never presented with monosomal karyotype (0% vs 23.1%, $P = .07$; supplemental Table 6).




Figure 1. Validation of the prognostic relevance of the knowledge bank approach. (A) OS of all 656 patients and (B) DFS of the 545 CR1 patients according to the KB score arbitrarily binned in 3 groups (KB score, <20, 20-39, ≥40). P values from log-rank tests.

One hundred eighty-five (66.5%) HSCT candidates and 91 (34.1%) chemotherapy-only candidates were transplanted in CR1 in the ALFA 0702 study. The repartition of the 66 transplanted beyond relapse is shown on Figure 3. In a time-dependent analysis, there was a strong interaction between this integrated transplant indication and the outcome of HSCT ($P = 1.5 \times 10^{-5}$). Transplantation in CR1 was detrimental in chemotherapy-only candidates (HR = 3.19; 95% CI, 1.81-5.61; $P = 5 \times 10^{-5}$) but was associated with a significant benefit in OS from the day 45 landmark in HSCT candidates (HR = 0.67; 95% CI, 0.47-0.96; $P = .03$; Simon-Makuch plot in supplemental Figure 11). Based on C-indexes and proportion of HSCT candidates, this stringent HSCT policy, requiring both an MRD-adjusted ELN 2017 intermediate or adverse risk and a KB score lower than 40 to indicate HSCT, represented an optimal compromise between prediction of HSCT benefit and number of patients requiring an HSCT compared with a liberal policy requiring either a nonfavorable MRD-adjusted ELN 2017 risk or a KB score lower than 40 or a transplant indication solely guided by either MRD-adjusted ELN 2017 or KB score (supplemental Figure 10).

Finally, in a landmark analysis at 6 months from inclusion, when 529 (97.1%) of the 545 HSCT-eligible patients were still alive and 201 (72.8%) of the 276 HSCTs in CR1 had been performed, the


OS of transplant recipients from the 6-month landmark was significantly longer (5-year OS, 58.4%; 95% CI, 48.4% to 70.3%) than that of nontransplanted patients (43.5%; 95% CI, 34.5% to 54.8%; $P = .01$) among HSCT candidates based on the stringent HSCT policy, whereas among chemotherapy-only candidates, HSCT significantly reduced OS (70.1%; 95% CI, 59.8% to 82.1% vs 84.5%; 95% CI, 77.7% to 91.8%; $P = .002$), again with a significant interaction between transplant indication and HSCT ($P = 9 \times 10^{-5}$; Figure 4).

Discussion

By studying a cohort of 656 patients prospectively enrolled in the ALFA-0702 trial with targeted sequencing of 41 genes, we showed that ELN 2017, *NPM1* MRD, and the KB algorithm can be integrated to refine HSCT indication in AML.

Our study population consisted of patients younger than 60 eligible for intensive chemotherapy, thus representing the core population of patients eligible for HSCT in daily practice. The high exhaustivity (92%) of centralized genomics and the multicentric nature of the ALFA-0702 academic trial limit the selection biases inherent to these studies. Indeed, the genetic spectrum in our cohort agreed with

Figure 2. Forest plot of interaction between ELN 2017 risk, *NPM1* MRD, and KB score threshold with HSCT in CR1. HR and 95% CI (in brackets) of the effect of HSCT in CR1 (as a time-dependent covariate) on OS after the day 45 landmark in the 545 patients eligible for HSCT in CR1 according to ELN 2017 risk, *NPM1* MRD (in the 143 assessed patients), or KB score threshold of 40. *P* values from interaction tests in bivariate Cox models.



previous findings in comparable populations.^{4,21} Only 1.4% of patients could not be classified in the ELN 2017 system. Although our analyses confirm the prognostic relevance of ELN risk system, we found limited differences in OS and DFS between patients with high and low allelic ratios of *FLT3*-ITDs, as also found by others.^{37,38} This result, which is discrepant from previous reports,^{6,39} stresses the need to review some of the modifications operated during the 2017 update of ELN guidelines on the basis of large consortiums.⁴⁰

We could confirm previous results on smaller patient cohorts regarding the clear superiority of KB over ELN stratification in predicting outcome,²⁴ with bootstrapped C-indexes of 68.9 vs 63.0, respectively, for the prediction of OS. These values notably point to the need for further improvement of ELN risk stratification. As previously shown,^{22,24} the predictive power of the KB is robust to missing data, although the clinical parameters unavailable in the ALFA-0702 trial (lactate dehydrogenase, hemoglobin, and splenomegaly) had limited individual predictive power in the KB dataset,²¹ and the genes not assessed by targeted sequencing in our study are infrequently mutated in AML and have limited prognostic impact.^{4,21,41} For graphical purposes, we discretized results from the KB predictions (Figure 2). C-indexes for such arbitrary discretization were still superior to ELN 2017 for OS and DFS, but how this continuous score should be implemented in daily practice for prognostication remains to be addressed.

Choosing who to transplant in CR1 remains the main question in the management of younger AML patients treated intensively. In recent years and in the absence of randomized trials, time-dependent analysis has become a robust tool to study the benefit of HSCT in defined patient subgroups.¹⁶⁻¹⁸ In the ALFA-0702, HSCT indication was guided by trial-specific criteria inspired by ELN 2010. As a result, the proportion of patients who underwent HSCT was, to some extent, balanced between ELN 2017 categories, thus limiting the biases inherent to these uncontrolled analyses. Information on donor availability was lacking in the ALFA-0702 study, precluding a formal donor vs no donor comparison. We confirmed that favorable risk AML does not benefit from HSCT in CR1,^{6-9,16-18} especially when accounting for *NPM1* MRD to reassign patients with a favorable genotype but a positive to the intermediate risk group and those with intermediate genotype but negative MRD to the favorable group.²⁰ However, even such an MRD-adjusted ELN risk stratification could not robustly identify the subset of patients with a clear survival benefit of HSCT after CR1.

The multistage model of Gerstung et al²² accounts for the risk of relapse and nonrelapse mortality at all times, thus theoretically allowing to capture the risks and benefits of performing an HSCT either in CR1 or later after relapse. In the KB development cohort, 12% of patients were predicted to derive an OS benefit >10% by timing HSCT in CR1. In our cohort, a similar approach led to identify 111 (20.4%) such CR1 patients, but we found no differential effect of HSCT in those patients (interaction test: *P* = .27; supplemental Results). It is possible that estimation of nonrelapse mortality by KB,




Figure 3. Flowchart of the 3-step development of a personalized approach to guide HSCT indication in CR1, successively integrating ELN 2017 risk, *NPM1* MRD, and KB score threshold. The subsets of patients assigned to the chemotherapy-only and the HSCT postremission strategies at each step are indicated by blue and red boxes, respectively.

which has been developed based on data from patients transplanted between 1993 and 2004 after different postremission consolidations,²¹ does not provide an accurate risk/benefit evaluation of HSCT in more recent decades, given the continued improvement of the procedure.² This stresses the need for a continuous update of KB with more recent datasets. Another caveat of the multistage model underlying the current KB algorithm is that it does not explicitly estimate the proportion of patients who can achieve a second CR after relapse and be successfully transplanted in CR2. However, the overall benefit of this strategy remains questionable.⁴²

We thus turned to an alternative way to refine HSCT indications based on KB predictions. Because the benefit of HSCT in CR1 has consistently been shown to be highest in patients with poor prognosis,^{2,17,22} we simulated the long-term (5-year) OS of each patient in a scenario without HSCT in CR1. Simulating survival rather than incidence of relapse may better capture the benefit of salvage on long-term outcome. The resulting KB score ranges from 0 to 100, with lower values indicating worse outcome. We identified a KB score of 40 or lower as the best threshold to identify the benefit of HSCT in CR1. Expectedly, there was a significant overlap between MRD-adjusted ELN 2017 and this KB guide rule for HSCT allocation. However, combining these systems reclassified 26.3% of intermediate and 8.8% of adverse risk patients in CR1 in the chemotherapy-only group that may not need HSCT in CR1. Although

some demographic, clinical, and molecular differences were identified between these reclassified patients and those from their cognate ELN 2017 risk category, none could substitute the KB approach, strengthening the relevance of this machine learning tool for accurate risk profiling in AML.

This combined stratification strongly interacted with the benefit of HSCT in both time-dependent and 6-month landmark analyses. The 278 transplant candidates derived a significant OS benefit from HSCT in CR1, when HSCT significantly impaired OS in the 267 chemotherapy-only candidates. This stratification seems superior to previous ones, where nonsignificant differences were found in the favorable risk group^{16,18} and supports integration of MRD and the KB algorithm to optimize the use of HSCT in CR1. Importantly, this stringent HSCT policy identified patients likely to benefit from transplant better than more liberal policies (supplemental Figure 10). This suggests that the current KB alone cannot substitute for MRD to identify among favorable-risk patients those at higher risk of relapse.^{20,43}

As with all machine learning approaches, the internal logic of the KB algorithm is a black box.⁴⁴ KB simulations can be made through web-based tools. We have derived a similar tool to guide HSCT indication according to our strategy in daily practice (<https://alfa-group.shinyapps.io/alfa-hsct/>).




Figure 4. Landmark analysis at 6 months of the impact of HSCT in CR1. Kaplan-Meier estimates for OS from a 6-month landmark of the 268 HSCT candidates and 261 chemotherapy-only candidates still alive at 6 months from inclusion (96.4% and 97.8% of the total HSCT and chemotherapy-only candidates, respectively; Figure 3) transplanted (N = 132 HSCT candidates, N = 69 chemotherapy-only candidates) or not transplanted (N = 136 HSCT candidates, N = 192 chemotherapy-only candidates) before the 6-month landmark. P values from log-rank tests and from the interaction term of a bivariate Cox model.

Further improvements in personalized HSCT decisions are needed. They will require refined multistage models, accounting for CR2 and transplant modalities, more recent patient data capturing the continued improvement in AML management,²³ such as new disease-modifying agents (eg, FLT3 inhibitors),⁴⁵ and progresses in transplantation techniques.⁴⁶ Finally, personalized predictions integrating recently developed prognostic gene expression profiles⁴⁷ or other MRD techniques suited for *NPM1* wildtype patients^{48,49} are an area of future investigation. Until then, implementation of our personalized, integrated, HSCT decision tool will require prospective evaluation in clinical trials integrating upfront chemotherapy with transplant strategy.

Acknowledgments

The authors thank all investigators and clinical research associates from the ALFA group, and Sandrine Geffroy, Maxime Bucci, and Fabien Subtil

for technical help. L.F. received grants from the Association Action Leucémies and Fondation I-SITE ULNE. R.I. is supported by grants from Association Laurette Fugain, Association Princesse Margot, Association pour la Recherche contre le Cancer, Fondation Leucémie Espoir, and Ligue Contre le Cancer. N.D. is supported by the North-West Canceropole (GIRCI AAP-AE 2018). This study was funded by the French National Institute (PHRC 2007/1911 and PRTK TRANSLA10-060).

Authorship

Contribution: L.F., B.D., and N.D. performed the sequencing analyses and interpreted the genomic data; A.L., L.F., B.D., N.D., and N.B. performed and interpreted MRD analyses; L.F. and R.I. designed the study, assembled and analyzed the data, and drafted the manuscript; H.D., C. Preudhomme, and R.I. supervised the study; X.T., S.d.B., J.-H.B., I.Y.-A., P.-Y.D., C.B., M.M., A.P., S.N., S.C., N.V., E.R., K.C.-L., D.C., S.M., B.D., P.T., E.L., C.R., D.L., C.G., J.L., J.-V.M., C. Pautas, and G.S. provided clinical data; P.S. analyzed the data; G.F. and P.-A.M. designed the web application; S.C. supervised management of the clinical data; C.T. centrally reviewed cytogenetics data; and all authors revised the manuscript and accepted its final version.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: L.F., 0000-0003-2808-4843; S.d.B., 0000-0002-8126-4942; N.D., 0000-0002-3927-1022; G.F., 0000-0003-0461-1573; I.Y.-A., 0000-0003-4524-8782; P.-Y.D., 0000-0003-0119-3548; C.R., 0000-0002-3332-4525; C.B., 0000-0002-3474-2577; S. Chantepie, 0000-0003-0457-2252; B.D., 0000-0001-6285-9273; H.D., 0000-0002-5454-6768; C. Preudhomme, 0000-0002-1267-9546; R.I., 0000-0003-2139-6262.

Correspondence: Raphael Itzykson, Service Hématologie Adultes, Hôpital Saint-Louis, 1 Av Claude Vellefaux, F-75010 Paris, France; e-mail: raphael.itzykson@aphp.fr.

Footnotes

Submitted 24 February 2020; accepted 5 August 2020; prepublished online on *Blood* First Edition 1 September 2020. DOI 10.1182/blood.2020005524.

*C. Preudhomme and R.I. contributed equally to this work.

Reasonable requests for deidentified individual participant data should be sent to the corresponding author.

The online version of this article contains a data supplement.

There is a *Blood* Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

REFERENCES

- Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. *Blood*. 2016;127(1):53-61.
- Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. *Blood*. 2016;127(1):62-70.
- Grimwade D, Walker H, Harrison G, et al; Medical Research Council Adult Leukemia Working Party. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. *Blood*. 2001;98(5):1312-1320.
- Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *N Engl J Med*. 2012;366(12):1079-1089.
- Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood*. 2010;115(3):453-474.
- Schlenk RF, Kayser S, Bullinger L, et al; German-Austrian AML Study Group. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. *Blood*. 2014;124(23):3441-3449.
- Pratcorona M, Brunet S, Nomdedéu J, et al; Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant *NPM1* mutation: relevance to post-remission therapy. *Blood*. 2013;121(14):2734-2738.

8. Versluis J, In 't Hout FE, Devillier R, et al. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. *Leukemia*. 2017;31(1):26-33.
9. Ho AD, Schetelig J, Bochtler T, et al; Study Alliance Leukemia. Allogeneic stem cell transplantation improves survival in patients with acute myeloid leukemia characterized by a high allelic ratio of mutant FLT3-ITD. *Biol Blood Marrow Transplant*. 2016;22(3):462-469.
10. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*. 2017;129(4):424-447.
11. Schlenk RF, Döhner K, Krauter J, et al; German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. *N Engl J Med*. 2008;358(18):1909-1918.
12. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. *JAMA*. 2009;301(22):2349-2361.
13. Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2015;21(11):1863-1869.
14. Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. *Blood*. 2015;126(8):1033-1040.
15. Rashidi A, Hamadani M, Zhang MJ, et al. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. *Blood Adv*. 2019;3(12):1826-1836.
16. Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. *J Clin Oncol*. 2010;28(4):586-595.
17. Cornelissen JJ, Breems D, van Putten WL, et al. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. *J Clin Oncol*. 2012;30(17):2140-2146.
18. Schlenk RF, Döhner K, Mack S, et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. *J Clin Oncol*. 2010;28(30):4642-4648.
19. Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. *J Clin Oncol*. 2013;31(23):2963-2969.
20. Balsat M, Renneville A, Thomas X, et al. Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the Acute Leukemia French Association Group. *J Clin Oncol*. 2017;35(2):185-193.
21. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. *N Engl J Med*. 2016;374(23):2209-2221.
22. Gerstung M, Papaemmanuil E, Martincorena I, et al. Precision oncology for acute myeloid leukemia using a knowledge bank approach. *Nat Genet*. 2017;49(3):332-340.
23. Burnett AK, Hills RK, Russell N. Twenty five years of UK trials in acute myeloid leukaemia: what have we learned? *Br J Haematol*. 2020;188(1):86-100.
24. Huet S, Paubelle E, Lours C, et al. Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life. *Blood*. 2018;132(8):865-867.
25. Cheson BD, Bennett JM, Kopecky KJ, et al; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. *J Clin Oncol*. 2003;21(24):4642-4649.
26. Sievers EL, Larson RA, Stadtmauer EA, et al; Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. *J Clin Oncol*. 2001;19(13):3244-3254.
27. Thomas X, de Botton S, Chevret S, et al. Randomized phase II study of clofarabine-based consolidation for younger adults with acute myeloid leukemia in first remission. *J Clin Oncol*. 2017;35(11):1223-1230.
28. Ruminy P, Marchand V, Buchbinder N, et al. Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemia. *Leukemia*. 2016;30(3):757-760.
29. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. *Biol Blood Marrow Transplant*. 2009;15(12):1628-1633.
30. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. *Stat Med*. 1986;5(3):255-260.
31. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. *Biometrika*. 1994;81(3):515-526.
32. O'Brien RM. A caution regarding rules of thumb for variance inflation factors. *Qual Quant*. 2007;41(5):673-690.
33. Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med*. 1996;15(4):361-387.
34. Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. *Stat Med*. 1984;3(1):35-44.
35. Mantel N, Byar DP. Evaluation of response-time data involving transient states: an illustration using heart-transplant data. *J Am Stat Assoc*. 1974;69(345):81-86.
36. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. *Ann Stat*. 1982;10(4):1100-1120.
37. Harada Y, Nagata Y, Kihara R, et al; Japan Adult Leukemia Study Group JALSG. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. *Leuk Res*. 2018;66:20-27.
38. Boddu PC, Kadia TM, Garcia-Manero G, et al. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. *Cancer*. 2019;125(7):1091-1100.
39. Dohner K, Thiede C, Jahn N, et al. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. *Blood*. 2019;135(5):371-380.
40. Angenendt L, Röllig C, Montesinos P, et al. Chromosomal abnormalities and prognosis in NPM1-mutated acute myeloid leukemia: a pooled analysis of individual patient data from nine international cohorts. *J Clin Oncol*. 2019;37(29):2632-2642.
41. Ley TJ, Miller C, Ding L, et al; Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med*. 2013;368(22):2059-2074.
42. Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. *Blood*. 2013;121(7):1077-1082.
43. Jourdan E, Boissel N, Chevret S, et al; French AML Intergroup. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. *Blood*. 2013;121(12):2213-2223.
44. Miotto R, Wang F, Wang S, Jiang X, Dudley JT. Deep learning for healthcare: review, opportunities and challenges. *Brief Bioinform*. 2018;19(6):1236-1246.
45. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. *N Engl J Med*. 2017;377(5):454-464.
46. Yu S, Huang F, Wang Y, et al. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. *Leukemia*. 2020;34(5):1433-1443.
47. Ng SW, Mitchell A, Kennedy JA, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. *Nature*. 2016;540(7633):433-437.
48. Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. *N Engl J Med*. 2018;378(13):1189-1199.
49. Freeman SD, Hills RK, Virgo P, et al. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. *J Clin Oncol*. 2018;36(15):1486-1497.